Objective To analyse comorbidity measures in relation to cardiovascular disease risk, using data from Swedish healthcare registries. The aim was to evaluate the performance of different indices in ...

Nearly one million Israelis live with chronic lung diseases such as asthma and COPD, and for them the current security reality, which has already lasted almost two weeks, may worsen their condition.

St. Mary’s Medical Center, part of Marshall Health Network, is launching a new COPD Community Screening Program to help identify individuals who may be at risk for Chronic ...

Chronic obstructive pulmonary disease, commonly called COPD, is a long-term lung condition that makes breathing difficult. It usually develops after many years of exposure to harmful particles, ...

The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...

A severe case of COVID-19 or influenza could increase the risk of lung cancer later on, according to new research. Scientists discovered that serious viral infections can alter immune cells in the ...

Chronic obstructive pulmonary disease (COPD) is known for causing breathing difficulties and limiting everyday activities. Obstructive sleep apnea syndrome (OSAS), on the other hand, is usually ...

As many as half of all nursing home patients may benefit from respiratory therapy, given rising complexity and common conditions such as COPD, congestive heart failure and other chronic breathing and ...

Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

Arrythmias were the heart conditions linked to the highest risk for death in patients admitted for severe anaphylaxis.

Title: 79594 - Rademikibart monotherapy in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD): A 1-year, phase III, randomized, double-blinded, placebo-controlled trial ...